Antoni Chan MD (Prof) synovialjoints
1 week 1 day ago
ACR50 at Week 4 was 19.9% (BKZ) vs 7.2% (RZB) nominal p<0.0001. Faster onset, higher sustained joint response. DAPSA LDA/remission 65% vs 55%. Dual IL-17A/F blockade outperforms IL-23 inhibition for joints in #PsA. Abstr LB0001 @RheumNow #EULAR2026 https://t.co/s4z8r1rKte
Jiha Lee JihaRheum
1 week 1 day ago
First head-to-head trial to show #PsA joint outcome superiority
BE BOLD: Bimekizumab (BKZ; IL-17A/F dual blockade) beat Risankizumab (RZB: IL-23i) on ACR50 at wk 16 (49.1% vs 38.4%, p=0.0078). BKZ also faster: ACR50 at wk 4 already 19.9% vs 7.2%.
@RheumNow #EULAR2026 LB0001 https://t.co/YMQCpom5xD
Nelly ZIADE 🍀 Nellziade
1 week 2 days ago
Do GLP-1 agonists achieve meaningful weight loss in patients with RMDs?
RISE registry
Retrospective
N=60,206
Tirzepatide: lost 8%
Semaglutide: list 6%
At 12 months
PsA had the highest usage
OP0112 #EULAR2026 @RheumNow https://t.co/P3CTgiwqCr
Nelly ZIADE 🍀 Nellziade
1 week 2 days ago
One of the highlights of #EULAR2026 for me:
♀️The "This Is a Woman's World" session
I recapped 8 must-know abstracts (including our work from ARCH_ArLAR) in a new @RheumNow video🎬
https://t.co/3jwJIegGg4 via @YouTube
@ArLARheumatolog https://t.co/Azvkl2sjdu
Dr. John Cush RheumNow
1 week 2 days ago
Beyond the Scale: Do GLP-1RAs Offer More Than Weight Loss in PsA?
Over 70% of patients with psoriatic arthritis (PsA) struggle with excess weight, amplifying synovio-entheseal inflammation and blunting biologic response.
https://t.co/pAIXkdazci https://t.co/vQTn3BWv2r
Jiha Lee JihaRheum
1 week 2 days ago
Do probiotics help in #PsA? First RCT (MEDIPSA) says no. Multispecies probiotic vs placebo in 66 pts: 43% vs 65% achieved low disease activity at wk 12 (p=0.167). Gut-joint axis intriguing, but probiotics not the answer yet. @RheumNow #EULAR2026 POS0290
Jiha Lee JihaRheum
1 week 2 days ago
What does remission really mean to patients with #PsA? The RemiPPsA international qualitative study asked 123 patients across 11 countries. Pain-free + ability to resume daily life topped the list, not just composite scores. #EULAR2026 @RheumNow, POS0294 https://t.co/mEGpkewuTX
Day 3 was an interesting mix of posters, oral presentations, and review sessions on many practical subjects like osteoarthritis, large vessel vasculitis, systemic sclerosis, and pregnancy. Here are a few of my recommended abstracts from Friday at EULAR 2026.
At EULAR 2026, Dr Nikolaos Kougkas presented data from a unique real-world cohort built within joint dermatology–rheumatology university centers, following 394 patients with psoriasis on bDMARDs for up to 17 years. We sat down with Dr Kougkas to unpack the methodology, challenge the results, and draw out the clinical implications for everyday practice.
